Skip to main content

Work experience

2011 - Present

Assistant Professor

Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Rīga Stradiņš University

2010 - Present

Leading Researcher

Laboratory of Pharmaceutical Pharmacology, Latvian Institute of Organic Synthesis

2007 - 2010

Researcher

Laboratory of Pharmaceutical Pharmacology, Latvian Institute of Organic Synthesis

2004 - 2007

Scientific Assistant

Laboratory of Pharmaceutical Pharmacology, Latvian Institute of Organic Synthesis

2006 - 2006

Lecturer

Faculty of Medicine, University of Latvia

2000 - 2004

Laboratory Assistant

Laboratory of beta-Diketones and Membrane Active Compounds, Latvian Institute of Organic Synthesis

Education and training

2005 - 2009

Dr.pharm.

University of Latvia

1999 - 2004

Pharmacist Degree

Rīga Stradiņš University

Achievements

Continuing education a.o. qualification upgrade

2016. 10.-11. Traineeship​ in Jagiellonian Centre for Experimental Therapeutics​, Kraków, Poland​

2010. 09.-10. Courses in laboratory animal science​, obtained FELASA C certificate Nr. 866, Stockholm, Sweden​

2008. 12. ADInstruments Workshop: Basic and Advanced analysis features of LabChart, Riga, Latvia​

2008. 08.-09. Baltic Summer School 2008, "Basic and clinical aspects of cardiac arrhythmia's" Copenhagen, Denmark​

2008. 01. Courses "Microsurgical techniques and radio-telemetry", Intrenational Microsurgical Training Centre, Lelystad, The Netherlands​​

2006. 04.-05. Traineeship​ in Department of Experimental Pharmacology of Jagiellonian University​, Kraków, Poland​​

Field of research

Drug discovery, medical chemistry, atherosclerosis, endothelial dysfunction, cardioprotection, rare cancers

Objects of intellectual property

Kalvins I., Vilskersts R., Pugovics O., Dambrova M., Stonans I., Kuka J., Liepins E., Loza E. Andrianovs V., Grinberga S., Gustina D., Lola D., Makrecka M. Use of 4-[ethyl(dimethyl)ammonio]butanoate or pharmaceuticaly acceptable salt in the treatment of atherosclerosis. WO2014096133

Stonans I., Kalvins I., Dambrova M., Svalbe B., Cirule H., Vilskersts R., Jonane-Osa I. Use of 3-(2,2,2-trimethylhydrazinium)-ethylpropionate or a pharmaceutically acceptable salt for treating high tension glaukoma. WO 2014/032735

Stonans I, Kalvins I, Dombrova M, Liepins E, Loza E, Lola D, Kuka J, Pugovics O, Vilskersts R, Grinberga S, Dambrova M. Use of 3-carboxy-N-ethyl-N,N-demethylpropan-1-amnium salts in the treatment of cardiovascular disease. Pat.nr. WO/2012/146736

Kalvins I, Dambrova M, Liepins E, Pugovics O, Vilskersts R, Kuka J, Grinberga S, Loza E. Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease. Pat.nr. WO/2011/048201.

Supervised study course

Drug Development

Medical Chemistry

Lectured study course

Medical Chemistry

Supervised and reviewed student research papers

Supervised:

Master's theses: 11

Reviewed:

doctoral theses: 4

Master's theses: 4

Projects

Project Scientific Manager, Research Department, Project „Development of New Anti-Cancer Agents for Treatment of Rare Tumours in Lupan-Row Triterpenoid Group" (2016-2018)

Investigator, RSU research project No. RSU ZP 09/2013 „Mitochondria-targeted drug and preparation evaluation in the ex vivo model of mitochondrial damage" (2013-2016)

Investigator, European Social Fund (ESF) project Nr. 2013/0003/1DP/1.1.1.2.0/13/ /APIA/VIAA/009: "Investigation of fatty acid energy metabolism for development of novel diagnostics and treatments of cardiovascular diseases" (2013-2015)

Project Scientific Manager,​ Research project of Taiho Foundation: "New approach to treat endothelial dysfunction" (2011-2012)

Investigator, ​European Regional Development Fund (ERAF) DP/2.1.1.1.0/10/APIA/VIAA/063 "Discovery of new cardioprotective compounds: Synthesis and investigation of GBB hydroxylase inhibitors" (2010-2013)

Memberships

2013.08.-Present The Centre for Disease Prevention and Control, Scientific expert​

2013.10.-Present Food and Veterinary Service, Scientific expert​

2011.01.-Present Member of Rīga Stradiņš University Promotion Council in Pharmacy.

2010.10. -Present Latvian Council of Science, Expert

Latvian Biochemical Society;

Latvian Pharmacological Society​

Awards and recognitions

2013. Listed in the top ten scientific developments in Latvia in scientific research: Completed preclinical studies of a novel cardioprotective drug. (Akad. M. Dambrova, Dr. S. Grīnberga, akad. I. Kalviņš, Dr. J. Kūka, Dr. E. Liepiņš, Dr. D. Loļa, Dr. E. Loža, LZA kor.loc. O. Pugovičs, Dr. R. Vilšķērsts; Dr. I. Stonāns; Latvian Institute of Organic Synthesis, JSC Grindeks.

2008. "Silver Owl"; JSC «Grindeks» fund "For the Support of Science and Education" in cooperation with the Latvian Academy of Sciences


Publications

Research articles​​


Inhibition of L-carnitine biosynthesis and transport by methyl-γ-butyrobetaine decreases fatty acid oxidation and protects against myocardial infarction / M.Makrecka-Kuka, R.Vilskersts, M.Dambrova ...[et al.] // British Journal of Pharmacology. - Vol.172, No.5 (2015, March), p.1319-1332. - Starptautiski citējamā izdevumā.


Methyl-γ-butyrobetaine decreases levels of acylcarnitines and attenuates the development of atherosclerosis / R.Vilskersts, J.Kuka, M.Dambrova ...[et al.] // Vascular Pharmacology. - Vol.72 (2015, Sept.), p.101-107. - Starptautiski citējamā izdevumā.


Magnesium nitrate attenuates blood pressure rise in SHR rats / R.Vilskersts, M.Dambrova, J.Kuka ...[et al.] // Magnesium Research. - Vol.27, No.1 (2014, Jan./March), p.16-24. - Starptautiski citējamā izdevumā.



Selective inhibition of OCTN2 is more effective than inhibition of gamma-butyrobetaine dioxygenase to decrease the availlability of I-carnitine and to reduce myocardial infarct size / R.Vilskersts, M.Makrecka, M.Dambrova ...[et al.] // Pharmacological Research. - Vol.85 (2014, July), p.33-38. - Starptautiski citējamā izdevumā.


The cognition-enhancing activity of E1R, a novel positive allosteric modulator of sigma-1 receptors / R.Vilskersts, M.Dambrova, E.Vavers ...[et al.] // British Journal of Pharmacology. - Vol.171, No.3 (2014, Febr.), p.761-771. - Starptautiski citējamā izdevumā.


The heart is better protected against myocardial infarction in the fed state compared to the fasted state / M.Makrecka, R.Vilskersts, M.Dambrova ...[et al.] // Metabolism : Clinical and Experimental. - Vol.63, No.1 (2014, Jan.), p.127-136. - Starptautiski citējamā izdevumā.



Elevated vascular γ-butyrobetaine levels attenuate the development of high glucose-induced endothelial dysfunction / R.Vilskersts, O.Zharkova-Malkova, M.Dambrova ...[et al.] // Clinical and Experimental Pharmacology & Physiology. - Vol.40, No.8 (2013, Aug.), p.518-524. - Starptautiski citējamā izdevumā.



Calcium level controlling activities of novel derivatives of amlodipine, riodipine and cerebrocrast / R.Vilskersts, B.Vigante, M.Dambrova ...[et al.] // Letters in drug desing & discovery. - Vol.9, N 3 (2012), p.322-328. - Starptautiski citējamā izdevumā.



Glyoxalase 1 and glyoxalase 2 activities in blood and neuronal tissue samples from experimental animal models of obesity and type 2 diabetes mellitus / I.Konrade, R.Vilskersts, M.Dambrova ...[et al.] // Journal of physiological sciences. - Vol.62, N 6 (2012, Nov.), p.469-478. - Starptautiski citējamā izdevumā.



The cardioprotective effect of mildronate is diminished after co-treatment with L-carnitine / J.Kuka, R.Vilskersts, M.Dambrova ...[et al.] // Journal of Cardiovascular Pharmacology and Therapeutics. - Vol.17, N 2 (2012), p.215-222. - Starptautiski citējamā izdevumā.



Administration of L-carnitine and mildronate improves endothelial function and decreases mortality in hypertensive Dahl rats / R.Vilskersts, J.Kuka, M.Dambrova ...[et al.] // Pharmacological reports. - Vol.63, N 3 (2011, May-June), p.752-762. - Starptautiski citējamā izdevumā.


Vilšķērsts, Reinis. Tasīte kafijas jūsu veselībai : [par saistību starp regulāru kafijas uzņemšanu un dažādu slimību attīstības risku] / R.Vilšķērsts // Latvijas Ārsts. - Nr.9 (2011), 64.-[67.]lpp.

Abstracts​​



Hlorofilīna un resveratrola vazoprotektīvie efekti hipohlorīta izraisītajā endotēlija disfunkcijas modelī in vitro / R.Vilšķērsts, D.Bandere, M.Dambrova ...[u.c.] // 2016.gada Zinātniskās konferences tēzes (Rīga, 2016.g. 17.-18.martā) / Rīgas Stradiņa universitāte. - Rīga, 2016. - 90.lpp.


Trimetilamīna N-oksīda ietekme uz sirds mitohondriālo enerģijas metabolismu / K.Voļska, R.Vilšķērsts, D.Bandere, M.Dambrova ...[u.c.] // 2016.gada Zinātniskās konferences tēzes (Rīga, 2016.g. 17.-18.martā) / Rīgas Stradiņa universitāte. - Rīga, 2016. - 69.lpp.



Trimetilamīna-N-oksīda (TMAO) noteikšanas preklīniskie faktori : diētas ietekme uz TMAO līmeni un interpretāciju / I.Konrāde, M.Dambrova, R.Vilšķērsts ...[u.c.] // 2016.gada Zinātniskās konferences tēzes (Rīga, 2016.g. 17.-18.martā) / Rīgas Stradiņa universitāte. - Rīga, 2016. - 47.lpp.


Attenuation of atherosclerosis development by targeting acylcarnitine pools / R.Vilskersts, M.Dambrova, K.Volska ...[et al.] // Drug Discovery Conference (Riga, Latvia, Aug.27-29, 2015) : Abstract Book. - Riga, 2015. - P.37.


Dual modality fluorescence and computed tomography system for in vivo imaging of neuro-inflammation [Elektroniskais resurss] : [abstract] / M.Dambrova, E.Vāvers, E.Liepiņš ...[et al.] // EU FP7 project GlowBrain Final Conference "Stem cell and biomaterial applications for brain repair" (Zagreb, Croatia, May 27-30, 2015) [Elektroniskais resurss]. - Zagreb, 2015. - 1 p. - Resurss aprakstīts 2016.g. 22.janv. - Pieejas veids: Tīmeklis WWW.URL: http://glowbrain.hiim.hr/images/FinalConf_abstracts/abstract_Dambrova.pdf


Effects of chlorophyllin and resveratrol on the sodium hypochlorite induced endothelial dysfunction / D.Bandere, M.Dambrova, R.Vilskersts ...[et al.] // Drug Discovery Conference (Riga, Latvia, Aug.27-29, 2015) : Abstract Book. - Riga, 2015. - P.94.


Experimental models for novel anti-diabetic and anti-obesity drug testing / K.Volska, R.Vilskersts, M.Dambrova ...[et al.] // Drug Discovery Conference (Riga, Latvia, Aug.27-29, 2015) : Abstract Book. - Riga, 2015. - P.120.


Experimental models for the development of new cardiovascular drugs / R.Vilskersts, J.Kuka, E.Liepins, M.Dambrova // Drug Discovery Conference (Riga, Latvia, Aug.27-29, 2015) : Abstract Book. - Riga, 2015. - P.158.



In vitro modelis mitohondriju funkcionalitātes novērtēšanai kardiovaskulāro un neirodeģeneratīvo slimību patoģenēzes pētījumiem un zāļu vielu skrīningam / R.Vilšķērsts, D.Bandere, M.Dambrova ...[u.c.] // 2015.gada Zinātniskās konferences tēzes (Rīga, 2015.g. 26.-27.martā) / Rīgas Stradiņa universitāte. - Rīga, 2015. - 63.lpp.


Metil-γ-butirobetaīns samazina acilkarnitīnu līmeni un aizkavē aterosklerozes attīstību / R.Vilšķērsts, M.Dambrova, K.Voļska ...[u.c.] // 2015.gada Zinātniskās konferences tēzes (Rīga, 2015.g. 26.-27.martā) / Rīgas Stradiņa universitāte. - Rīga, 2015. - 62.lpp.


Novel positive allosteric modulators of sigma-1 receptor [Elektroniskais resurss] / R.Vilskersts, M.Dambrova, E.Vavers ...[et al.] // SpringerPlus [Elektroniskais resurss]. - Vol.4, Suppl.1 (2015, Apr.), Poster No.51, p.30. - European Society for Neurochemistry Biannual Conference: Molecular Mechanisms of Regulation in the Nervous System (Tartu, Estonia, June 14-17, 2015) : Meeting Abstracts. - Pieejas veids: Tīmeklis WWW.URL: http://www.springerplus.com/content/pdf/2193-1801-4-S1-P51.pdf


Stereoselective pharmacological activity of 4.5-disubstituted piracetam derivatives, positive allosteric modulators of sigma-1 receptor / E.Vavers, R.Vilskersts, M.Dambrova ...[et al.] // Drug Discovery Conference (Riga, Latvia, Aug.27-29, 2015) : Abstract Book. - Riga, 2015. - P.62, 156.


Taregting acylcarnitine content in vascular tissue to attenuate development of atherosclerosis / R.Vilskersts, J.Kuka, M.Dambrova ...[et al.] // Atherosclerosis. - Vol.241, Issue 1 (2015, July), p.e95. - Starptautiski citējamā izdevumā.


Trimetilamīna-N-oksīds – L-karnitīna metabolīts un jauns kardiometabolo risku marķieris / M.Dambrova, I.Konrāde, I.Strēle, R.Vilšķērsts ...[u.c.] // 2015.gada Zinātniskās konferences tēzes (Rīga, 2015.g. 26.-27.martā) / Rīgas Stradiņa universitāte. - Rīga, 2015. - 50.lpp.


Discovery of a novel regulator of cardiac energy metabolism, cardioprotective drug methyl-GBB / M.Dambrova, M.Makrecka, R.Vilskersts ...[et al.] // Basic & Clinical Pharmacology & Toxicology. - Vol.115, Suppl.1 (2014, July), p.19. - Starptautiski citējamā izdevumā.


Elevated vascular gamma-butyrobetaine is protective in high glucose induced endothelial dysfunction / R.Vilskersts, O.Zharkova-Malkova, R.Mezhapuke, M.Dambrova // The 29th Congress of the Federation of the International Danube Symposia on Diabetes mellitus (Jurmala, Latvia, June 24-28, 2014) : Book of Abstracts. - Jurmala, 2014. - P.38.


Gamma-butirobetaīna vazoprotektīvie efekti eksperimentālajos in vitro modeļos / R.Vilšķērsts, D.Bandere, M.Dambrova ...[u.c.] // 2014.gada Zinātniskās konferences tēzes (Rīga, 2014.g. 10.-11.aprīlī) / Rīgas Stradiņa universitāte. - Rīga, 2014. - 79.lpp.


Hypotensive effects of magnesium nitrate in SHR rats / R.Vilskersts, J.Kuka, M.Dambrova ...[et al.] // Basic & Clinical Pharmacology & Toxicology. - Vol.115, Suppl.1 (2014, July), p.31. - Starptautiski citējamā izdevumā.


Sigma-1 receptoru pozitīva alostēriska modulēšana uzlabo kognitīvo funkciju / R.Vilšķērsts, M.Dambrova, E.Vāvers ...[u.c.] // 2014.gada Zinātniskās konferences tēzes (Rīga, 2014.g. 10.-11.aprīlī) / Rīgas Stradiņa universitāte. - Rīga, 2014. - 89.lpp.


The difference spectrum of activity of synthetic interferon inductors / M.Dambrova, R.Vilskersts, V.Bulgakova ...[et al.] // Archives of Disease in Childhood. - Vol.99, Suppl.2 (2014, Oct.), p.A553. - Starptautiski citējamā izdevumā.


Jauns sigma-1 receptoru pozitīvs allostērisks modulators ar atmiņu uzlabojošu darbību / R.Vilšķērsts, M.Dambrova, V.Ķīsis ...[u.c.] // 2013.gada Zinātniskās konferences tēzes (Rīga, 2013.g. 21.-22.martā) / Rīgas Stradiņa universitāte. - Rīga, 2013. - 117.lpp.


Magnija nitrāta ievadīšanas ietekme uz hipertensijas izraisītajām komplikācijām / R.Vilšķērsts, M.Dambrova, J.Kūka ...[u.c.] // 2013.gada Zinātniskās konferences tēzes (Rīga, 2013.g. 21.-22.martā) / Rīgas Stradiņa universitāte. - Rīga, 2013. - 120.lpp.


Sirds išēmijas-reperfūzijas bojājums pēc ēšanas un tukšā dūšā : pētījumi žurku eksperimentālajos modeļos / R.Vilšķērsts, M.Dambrova, M.Makrecka ...[u.c.] // 2013.gada Zinātniskās konferences tēzes (Rīga, 2013.g. 21.-22.martā) / Rīgas Stradiņa universitāte. - Rīga, 2013. - 86.lpp.


Protective effects of reduction of L-carnitine pools in experimental models of cardiovascular diseases and diabetes / R.Vilskersts, M.Dambrova, J.Kuka ...[et al.] // 2012.gada Zinātniskās konferences tēzes (Rīga, 2012.g. 29.-30.martā) / Rīgas Stradiņa universitāte. - Rīga, 2012. - 83.lpp.


The role of vascular tissue gamma-butyrobetaine and L-carnitine content in angioprotection / R.Vilskersts, M.Dambrova, J.Kuka ...[et al.] // International Conference in Pharmacology "Targeting cellular regulatory systems" (Riga, Latvia, Apr.20-21, 2012) : Abstract Book. - Riga, 2012. - P.23.


Mildronāta kardioprotektīvā efekta saistība ar L-karnitīna koncentrācijas izmaiņām sirdī / R.Vilšķērsts, R.Medne, M.Dambrova ...[u.c.] // 2011.gada Zinātniskās konferences tēzes (Rīga, 2011.g. 14.-15.aprīlī) / Rīgas Stradiņa universitāte. - Rīga, 2011. - 75.lpp.


The cardioprotective effect of mildronate is associated with decreased CPT I-dependent fatty acid metabolism in mitochondria / M.Makrecka, J.Kuka, R.Vilskersts, M.Dambrova // Heart. - Vol.97, N 24 (2011, Dec.), p.e8. - Starptautiski citējamā izdevumā.

Contacts

Related news

Colleagues

Santa Purviņa
Head of the Department, Deputy Chair
Maija Dambrova
Academic Staff
Dace Bandere
Dean, Head of the Department, Head of Study Programme, Academic Staff
Baiba Mauriņa
Vice-Dean, Head of Study Programme, Academic Staff
Elita Poplavska
Head of the Department, Leading Researcher
Pāvels Sudmalis
Academic Staff, Researcher
Inga Urtāne
Acting Head of Department, Academic Staff